Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China

AIM: That clinical trial (RAINBOW) showed that a 7.4 months overall survival benefit with the combination therapy with ramucirumab (RAM) and paclitaxel (PAC) as second-line therapy for patients with recurrent or metastatic gastric or gastro-oesophageal junction adenocarcinoma, compared with placebo...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:PLoS One
Main Authors: Li, Sini, Peng, Liubao, Tan, Chongqing, Zeng, Xiaohui, Wan, Xiaomin, Luo, Xia, Yi, Lidan, Li, Jianhe
Format: Artigo
Sprog:Inglês
Udgivet: Public Library of Science 2020
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7205241/
https://ncbi.nlm.nih.gov/pubmed/32379763
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0232240
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker